We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nexavar Receives Priority Review For Kidney Cancer Product
Nexavar Receives Priority Review For Kidney Cancer Product
August 24, 2007
The FDA has granted priority review status for Bayer Healthcare and Onyx Pharmaceuticals’ cancer agent Nexavar for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer, the companies announced Aug. 20.